{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T15:26:05Z","timestamp":1753889165661,"version":"3.37.3"},"reference-count":20,"publisher":"Scientific Scholar","issue":"04","license":[{"start":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T00:00:00Z","timestamp":1686614400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Lab Physicians"],"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>\n          Introduction and Objectives\u2003The availability of a limited arsenal of antibacterial agents effective against Burkholderia pseudomallei, the causative agent of melioidosis, together with sporadic reports of emergence of resistance necessitates an evaluation of in vitro activity of new antimicrobials against clinical B. pseudomallei isolates. Cefiderocol (CFDC), a novel siderophore cephalosporin, and ceftazidime-avibactam (CZA), a new \u03b2 lactam combination agent, have shown promising results for the treatment of difficult-to-treat Gram-negative bacilli infections with limited treatment options. This study was conducted to determine the in vitro activity of CFDC and CZA against a contemporary collection of 60 B. pseudomallei clinical isolates.<\/jats:p><jats:p>\n          Materials and Methods\u2003Minimum inhibitory concentrations (MIC) of CFDC and CZA were determined by broth microdilution and E-test, respectively. The performance of disk diffusion was also evaluated for CFDC.<\/jats:p><jats:p>\n          Results\u2003All B. pseudomallei isolates were susceptible to CFDC and CZA with MIC range of 0.125 to 2\u2009mg\/L and 0.19 to 1\u2009mg\/L, respectively. Zone diameters for CFDC ranged from 31 to 40\u2009mm.<\/jats:p><jats:p>\n          Conclusion\u2003CFDC and CZA exhibited excellent in vitro activity against 60 B. pseudomallei isolates. Further pharmacokinetic-pharmacodynamics studies and clinical trials are needed to prove the clinical efficacy of CFDC and CZA in the treatment of melioidosis.<\/jats:p>","DOI":"10.1055\/s-0043-1770067","type":"journal-article","created":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T23:13:52Z","timestamp":1686698032000},"page":"573-577","source":"Crossref","is-referenced-by-count":3,"title":["In Vitro Susceptibility of Burkholderia pseudomallei Isolates to Cefiderocol and Ceftazidime\/Avibactam from Odisha, India"],"prefix":"10.25259","volume":"15","author":[{"given":"Jayanti","family":"Jena","sequence":"additional","affiliation":[{"name":"Department of Microbiology, All India Institute of Medical Sciences (AIIMS), Bhubaneswar, Odisha, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4123-7990","authenticated-orcid":false,"given":"Bijayini","family":"Behera","sequence":"additional","affiliation":[{"name":"Department of Microbiology, All India Institute of Medical Sciences (AIIMS), Bhubaneswar, Odisha, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gayatree","family":"Nayak","sequence":"additional","affiliation":[{"name":"Department of Microbiology, All India Institute of Medical Sciences (AIIMS), Bhubaneswar, Odisha, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6706-0660","authenticated-orcid":false,"given":"Srujana","family":"Mohanty","sequence":"additional","affiliation":[{"name":"Department of Microbiology, All India Institute of Medical Sciences (AIIMS), Bhubaneswar, Odisha, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashoka","family":"Mahapatra","sequence":"additional","affiliation":[{"name":"Department of Microbiology, All India Institute of Medical Sciences (AIIMS), Bhubaneswar, Odisha, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prashanth","family":"Purushotham","sequence":"additional","affiliation":[{"name":"Department of Microbiology, All India Institute of Medical Sciences (AIIMS), Bhubaneswar, Odisha, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6284-4557","authenticated-orcid":false,"given":"Anjuna","family":"Radhakrishnan","sequence":"additional","affiliation":[{"name":"Department of Microbiology, All India Institute of Medical Sciences (AIIMS), Bhubaneswar, Odisha, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manaswiny","family":"Tripathy","sequence":"additional","affiliation":[{"name":"Department of Microbiology, All India Institute of Medical Sciences (AIIMS), Bhubaneswar, Odisha, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10894","published-online":{"date-parts":[[2023,6,13]]},"reference":[{"issue":"09","key":"ref1","doi-asserted-by":"crossref","first-page":"e0008659","DOI":"10.1371\/journal.pntd.0008659","article-title":"2020 Review and revision of the 2015 Darwin melioidosis treatment guideline; paradigm drift not shift","volume":"14","author":"R P Sullivan","year":"2020","journal-title":"PLoS Negl Trop Dis"},{"issue":"12","key":"ref2","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.2217\/fmb.12.116","article-title":"Mechanisms of antibiotic resistance in Burkholderia pseudomallei: implications for treatment of melioidosis","volume":"7","author":"H P Schweizer","year":"2012","journal-title":"Future Microbiol"},{"issue":"02","key":"ref3","doi-asserted-by":"crossref","first-page":"e30789","DOI":"10.1371\/journal.pone.0030789","article-title":"Characterization of ceftazidime resistance mechanisms in clinical isolates of Burkholderia pseudomallei from Australia","volume":"7","author":"D S Sarovich","year":"2012","journal-title":"PLoS One"},{"issue":"41","key":"ref4","doi-asserted-by":"crossref","first-page":"17165","DOI":"10.1073\/pnas.1111020108","article-title":"Antimicrobial resistance to ceftazidime involving loss of penicillin-binding protein 3 in Burkholderia pseudomallei","volume":"108","author":"N Chantratita","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"129","DOI":"10.2147\/IDR.S35529","article-title":"Development of ceftazidime resistance in an acute Burkholderia pseudomallei infection","volume":"5","author":"D S Sarovich","year":"2012","journal-title":"Infect Drug Resist"},{"issue":"12","key":"ref6","doi-asserted-by":"crossref","first-page":"945","DOI":"10.47102\/annals-acadmedsg.V39N12p945","article-title":"Development of ceftazidime resistance in Burkhoderia pseudomallei in a patient experiencing melioidosis with mediastinal lymphadenitis","volume":"39","author":"C T Kung","year":"2010","journal-title":"Ann Acad Med Singap"},{"issue":"04","key":"ref7","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S1995-7645(12)60050-9","article-title":"Ceftazidime resistance in Burkholderia pseudomallei: first report from India","volume":"5","author":"B Behera","year":"2012","journal-title":"Asian Pac J Trop Med"},{"issue":"02","key":"ref8","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1093\/cid\/ciy069","article-title":"Raising the Stakes: loss of efflux pump regulation decreases meropenem susceptibility in Burkholderia pseudomallei","volume":"67","author":"D S Sarovich","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"06","key":"ref9","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1093\/jac\/dkab015","article-title":"Cefiderocol: a novel siderophore cephalosporin for multidrug-resistant gram-negative bacterial infections","volume":"76","author":"K A Parsels","year":"2021","journal-title":"J Antimicrob Chemother"},{"issue":"06","key":"ref10","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s40265-018-0902-x","article-title":"Ceftazidime-avibactam: a review in the treatment of serious gram-negative bacterial infections","volume":"78","author":"M Shirley","year":"2018","journal-title":"Drugs"},{"issue":"07","key":"ref11","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1111\/tmi.12894","article-title":"Improved detection of Burkholderia pseudomallei from non-blood clinical specimens using enrichment culture and PCR: narrowing diagnostic gap in resource-constrained settings","volume":"22","author":"C Tellapragada","year":"2017","journal-title":"Trop Med Int Health"},{"author":"Clinical and Laboratory Standards Institute","key":"ref12"},{"author":"Clinical and Laboratory Standards Institute","key":"ref13"},{"issue":"02","key":"ref14","doi-asserted-by":"crossref","first-page":"e00685","DOI":"10.1128\/AAC.00685-20","article-title":"Burkholderia pseudomallei clinical isolates are highly susceptible in vitro to cefiderocol, a siderophore cephalosporin","volume":"65","author":"D Burnard","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1093\/ofid\/ofw172.1380","article-title":"S-649266, a novel siderophore cephalosporin: in vitro activity against biothreat pathogen","volume":"3","author":"M Tsuji","year":"2016","journal-title":"Open Forum Infect Dis"},{"issue":"01","key":"ref16","doi-asserted-by":"crossref","first-page":"e01649","DOI":"10.1128\/JCM.01649-20","article-title":"Cefiderocol antimicrobial susceptibility testing against multidrug-resistant gram-negative Bacilli: a comparison of disk diffusion to broth microdilution","volume":"59","author":"C P Morris","year":"2020","journal-title":"J Clin Microbiol"},{"issue":"08","key":"ref17","doi-asserted-by":"crossref","first-page":"1156.e1","DOI":"10.1016\/j.cmi.2022.04.013","article-title":"Comparison of disk diffusion, MIC test strip and broth microdilution methods for cefiderocol susceptibility testing on carbapenem-resistant enterobacterales","volume":"28","author":"R A Bonnin","year":"2022","journal-title":"Clin Microbiol Infect"},{"issue":"06","key":"ref18","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1093\/jac\/dkac080","article-title":"Cefiderocol: EUCAST criteria for disc diffusion and broth microdilution for antimicrobial susceptibility testing","volume":"77","author":"E Matuschek","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jgar.2021.11.015","article-title":"In vitro susceptibility of Burkholderia pseudomallei isolates from Thai patients to ceftolozane\/tazobactam and ceftazidime\/avibactam","volume":"28","author":"W Sribenjalux","year":"2022","journal-title":"J Glob Antimicrob Resist"},{"issue":"05","key":"ref20","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.ijantimicag.2019.01.003","article-title":"Burkholderia pseudomallei acquired ceftazidime resistance due to gene duplication and amplification","volume":"53","author":"S Chirakul","year":"2019","journal-title":"Int J Antimicrob Agents"}],"container-title":["Journal of Laboratory Physicians"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0043-1770067.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,24]],"date-time":"2023-12-24T08:21:46Z","timestamp":1703406106000},"score":1,"resource":{"primary":{"URL":"https:\/\/jlabphy.org\/in-vitro-susceptibility-of-burkholderia-pseudomallei-isolates-to-cefiderocol-and-ceftazidime-avibactam-from-odisha-india\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,13]]},"references-count":20,"journal-issue":{"issue":"04","published-online":{"date-parts":[[2023,9,28]]},"published-print":{"date-parts":[[2023,12]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0043-1770067","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0974-2727","0974-7826"],"issn-type":[{"type":"print","value":"0974-2727"},{"type":"electronic","value":"0974-7826"}],"subject":[],"published":{"date-parts":[[2023,6,13]]}}}